Engineered immune cells take on breast cancer
NCT ID NCT04430595
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a new treatment using specially engineered immune cells (4SCAR-T cells) that target three different markers on breast cancer cells: GD2, Her2, and CD44v6. The goal is to see if this approach is safe and can shrink tumors in people with advanced or relapsed breast cancer. Up to 100 adults aged 18 to 75 with stage III, IV, or relapsed breast cancer will receive infusions of these cells.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
4SCAR-T cells targeting GD2, Her2, and CD44v6
What this could lead to
If it works, this could offer a new treatment option for advanced breast cancer that has not responded to standard therapies.
What could go wrong
This is an early-phase trial (Phase 1/2) with only 100 participants, so results may not apply to all patients. CAR-T therapy can cause serious side effects like cytokine release syndrome.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shenzhen Geno-immuno Medical Institute
RECRUITINGShenzhen, Guangdong, 518000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••